Catalyst Pharmaceuticals, Inc.
US ˙ NasdaqCM ˙ US14888U1016

SecurityCPRX / Catalyst Pharmaceuticals, Inc.
InstitutionAmundi
Latest Disclosed Ownership31,463 shares
Latest Disclosed Value $ 779,023
Amundi reports 68.39% increase in ownership of CPRX / Catalyst Pharmaceuticals, Inc.

On May 15, 2026 - Amundi filed a 13F-HR form disclosing ownership of 31,463 shares of Catalyst Pharmaceuticals, Inc. (US:CPRX) valued at $779,024 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 18,685 shares of Catalyst Pharmaceuticals, Inc.. This represents a change in shares of 68.39% during the quarter. The current value of the position is $984,163 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F CATALYST PHARMACEUTICALS COM 14888U101 31,463 12,778 68.39 779 78.67 0.0001
2026-02-17 2025-12-31 13F CATALYST PHARMACEUTICALS COM 14888U101 18,685 -1,845 -8.99 436 2.59 0.0001
2025-11-14 2025-09-30 13F CATALYST PHARMACEUTICALS COM 14888U101 20,530 1,843 9.86 426 6.25 0.0001
2025-08-13 2025-06-30 13F CATALYST PHARMACEUTICALS COM 14888U101 18,687 -26,444 -58.59 401 -63.24 0.0001
2025-05-15 2025-03-31 13F CATALYST PHARMACEUTICALS COM 14888U101 45,131 -11,478 -20.28 1,088 -15.66 0.0004
2025-02-07 2024-12-31 13F CATALYST PHARMACEUTICALS COM 14888U101 56,609 36,968 188.22 1,291 227.41 0.0004
2024-11-13 2024-09-30 13F CATALYST PHARMACEUTICALS COM 14888U101 19,641 2,905 17.36 394 53.91 0.0001
2024-08-14 2024-06-30 13F CATALYST PHARMACEUTICALS COM 14888U101 16,736 -2,926 -14.88 256 -14.95 0.0001
2024-05-15 2024-03-31 13F CATALYST PHARMACEUTICALS COM 14888U101 19,662 6,503 49.42 302 49.75 0.0001
2024-02-14 2023-12-31 13F CATALYST PHARMACEUTICALS COM 14888U101 13,159 616 4.91 201 25.63 0.0001
2023-11-14 2023-09-30 13F CATALYST PHARMACEUTICALS COM 14888U101 12,543 1 0.01 160 0.00 0.0001
2023-08-14 2023-06-30 13F CATALYST PHARMACEUTICALS COM 14888U101 12,542 12,542 160 0.0001
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.